Poseida Therapeutics (NASDAQ:PSTX) Earns “Neutral” Rating from HC Wainwright

HC Wainwright reiterated their neutral rating on shares of Poseida Therapeutics (NASDAQ:PSTX) in a research report released on Tuesday, MarketBeat reports. HC Wainwright currently has a $9.00 price target on the stock, down from their previous price target of $20.00.

Poseida Therapeutics Trading Down 0.5 %

Poseida Therapeutics stock opened at $9.33 on Tuesday. Poseida Therapeutics has a 12 month low of $1.87 and a 12 month high of $9.42. The company has a market capitalization of $909.35 million, a price-to-earnings ratio of -14.81 and a beta of 0.54. The business’s fifty day simple moving average is $3.14 and its two-hundred day simple moving average is $3.05. The company has a current ratio of 3.20, a quick ratio of 3.20 and a debt-to-equity ratio of 0.68.

Insider Buying and Selling at Poseida Therapeutics

In other Poseida Therapeutics news, Chairman Mark J. Gergen sold 30,000 shares of the stock in a transaction on Tuesday, November 26th. The stock was sold at an average price of $9.27, for a total transaction of $278,100.00. Following the sale, the chairman now directly owns 651,291 shares in the company, valued at approximately $6,037,467.57. This trade represents a 4.40 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 2.90% of the stock is owned by company insiders.

Institutional Inflows and Outflows

A number of hedge funds and other institutional investors have recently modified their holdings of the business. The Manufacturers Life Insurance Company raised its position in Poseida Therapeutics by 14.2% in the 2nd quarter. The Manufacturers Life Insurance Company now owns 28,520 shares of the company’s stock worth $83,000 after buying an additional 3,552 shares during the last quarter. Rhumbline Advisers grew its stake in shares of Poseida Therapeutics by 4.2% in the second quarter. Rhumbline Advisers now owns 97,012 shares of the company’s stock worth $283,000 after acquiring an additional 3,875 shares during the period. American Century Companies Inc. raised its holdings in shares of Poseida Therapeutics by 5.9% during the second quarter. American Century Companies Inc. now owns 90,487 shares of the company’s stock valued at $264,000 after purchasing an additional 5,023 shares during the last quarter. Dimensional Fund Advisors LP lifted its position in Poseida Therapeutics by 1.6% during the second quarter. Dimensional Fund Advisors LP now owns 599,812 shares of the company’s stock valued at $1,749,000 after purchasing an additional 9,672 shares during the period. Finally, Bayesian Capital Management LP bought a new position in Poseida Therapeutics during the first quarter valued at approximately $33,000. 46.87% of the stock is owned by institutional investors.

Poseida Therapeutics Company Profile

Poseida Therapeutics, Inc, a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications.